FDX1 regulation with a combination of immuno-checkpoint inhibitor therapy and chemotherapy drugs to promote the antitumor immunotherapy of multiform cancers will contribute to our development of antitumor drugs in the future. This evidence concerns the gene FDX1 and cancer.